Nascent Biotech, Inc.
NBIO
$0.0007
-$0.0001-12.50%
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 297.60K | 319.50K | 138.20K | 136.50K | 136.50K |
| Gross Profit | -297.60K | -319.50K | -138.20K | -136.50K | -136.50K |
| SG&A Expenses | 1.63M | 1.71M | 1.69M | 1.77M | 1.29M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.09M | 2.23M | 2.25M | 2.36M | 2.05M |
| Operating Income | -2.09M | -2.23M | -2.25M | -2.36M | -2.05M |
| Income Before Tax | -1.92M | -2.09M | -2.09M | -2.73M | -2.04M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.92 | -2.09 | -2.09 | -2.73 | -2.04 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.92M | -2.09M | -2.09M | -2.73M | -2.04M |
| EBIT | -2.09M | -2.23M | -2.25M | -2.36M | -2.05M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 655.99M | 625.28M | 583.75M | 536.01M | 504.70M |
| Average Diluted Shares Outstanding | 655.99M | 625.28M | 583.75M | 536.01M | 504.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |